928 related articles for article (PubMed ID: 27129488)
21. Mixed Pluronic/lecithin micelles formulation for oral bioavailability of candesartan cilexetil drug:
Mahajan H; Patel HS; Ray D; Aswal VK; Sharma RK; Tandel H
Drug Dev Ind Pharm; 2024 Jan; 50(1):23-35. PubMed ID: 38079333
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.
Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X
Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039
[TBL] [Abstract][Full Text] [Related]
23. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
[TBL] [Abstract][Full Text] [Related]
24. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
25. New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats.
AbuElfadl A; Boughdady M; Meshali M
Int J Nanomedicine; 2021; 16():5581-5601. PubMed ID: 34429601
[TBL] [Abstract][Full Text] [Related]
26. Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.
Sezgin-Bayindir Z; Antep MN; Yuksel N
AAPS PharmSciTech; 2015 Feb; 16(1):108-17. PubMed ID: 25204859
[TBL] [Abstract][Full Text] [Related]
27. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
28. Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process.
Kim MS; Baek IH
Int J Nanomedicine; 2014; 9():5167-76. PubMed ID: 25404856
[TBL] [Abstract][Full Text] [Related]
29. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study.
Detroja C; Chavhan S; Sawant K
Sci Pharm; 2011; 79(3):635-51. PubMed ID: 21886909
[TBL] [Abstract][Full Text] [Related]
30. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation.
Jiang T; Han N; Zhao B; Xie Y; Wang S
Drug Dev Ind Pharm; 2012 Oct; 38(10):1230-9. PubMed ID: 22229827
[TBL] [Abstract][Full Text] [Related]
31. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
33. Polymorphic and Quantum Chemistry Characterization of Candesartan Cilexetil: Importance for the Correct Drug Classification According to Biopharmaceutics Classification System.
de Campos DP; Silva-Barcellos NM; Lima RR; Savedra RML; Siqueira MF; Yoshida MI; da Nova Mussel W; de Souza J
AAPS PharmSciTech; 2018 Oct; 19(7):3019-3028. PubMed ID: 30062540
[TBL] [Abstract][Full Text] [Related]
34. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
Eur J Pharm Sci; 2017 Nov; 109():503-513. PubMed ID: 28889028
[TBL] [Abstract][Full Text] [Related]
35. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations.
Yuksel N; Bayindir ZS; Aksakal E; Ozcelikay AT
Int J Biol Macromol; 2016 Jan; 82():453-63. PubMed ID: 26455402
[TBL] [Abstract][Full Text] [Related]
36. Preparation and Evaluation of Diosgenin Nanocrystals to Improve Oral Bioavailability.
Liu CZ; Chang JH; Zhang L; Xue HF; Liu XG; Liu P; Fu Q
AAPS PharmSciTech; 2017 Aug; 18(6):2067-2076. PubMed ID: 27995466
[TBL] [Abstract][Full Text] [Related]
37. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation.
Surampalli G; Nanjwade BK; Patil PA; Chilla R
Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228
[TBL] [Abstract][Full Text] [Related]
38. Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: formulation optimization, characterization, analgesic and acute toxicity studies.
Rahim H; Sadiq A; Khan S; Khan MA; Shah SMH; Hussain Z; Ullah R; Shahat AA; Ibrahim K
Drug Des Devel Ther; 2017; 11():2443-2452. PubMed ID: 28860715
[TBL] [Abstract][Full Text] [Related]
39. Domperidone nanocrystals with boosted oral bioavailability: fabrication, evaluation and molecular insight into the polymer-domperidone nanocrystal interaction.
Ndlovu ST; Ullah N; Khan S; Ramharack P; Soliman M; de Matas M; Shahid M; Sohail M; Imran M; Shah SWA; Hussain Z
Drug Deliv Transl Res; 2019 Feb; 9(1):284-297. PubMed ID: 30387048
[TBL] [Abstract][Full Text] [Related]
40. Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size.
Pi J; Liu Z; Wang H; Gu X; Wang S; Zhang B; Luan H; Zhu Z
Curr Drug Deliv; 2016; 13(8):1358-1366. PubMed ID: 26953239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
